FWIW, it isn't just Dew. We worked up Peregrine back in June 2010 and passed on it because of insufficiency of their earlier trials. We thought the risk too high until after the current crop of Phase II data were in.
When we pass on a company we usualy don't write it up, but we did on this one.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr